Rosuvastatin Effect on Reducing Coronary Atherosclerosis Plaques Volume

Inclusion Criteria: * Written informed consent * Men or women, aged 18 -75 * Diagnosed with coronary heart disease (CHD) stable angina for more than 1 month and meet the following any one: 1. History of myocardial infarction. 2. CHD confirmed by coronary angiography. 3. Excercise ECG positive for CHD or perfusion defect 4. One or more main branch of coronary artery stenosis ≥ 50% confirmed by CT scanning. * Hyperlipidemia (lipid-lowering treatment naïve: LDL-C ≥130mg/dl, or having received lipid-lowering treatment: LDL-C ≥100mg/dl) * The 64 slice CT shows at least one significant coronary artery stenosis ≥20% with the narrowest ≤60% and meeting the following criteria: 1. Diameter of coronary artery lesion ≥2mm, length ≥5mm; distance between multiple lesions \>1cm 2. Plaque density \<100HU, no calcification 3. Vascular stenosis (20～60%) caused by plaques 4. Plaque thickness \>1mm 5. Plaque not in the coronary artery with previous PCI treatment. Exclusion Criteria: * Acute myocardial infarction within 6 months * PCI or CABG therapy within 6 months * Anticipated PCI or CABG therapy in the following 3 months. * Tropnin I/Tropnin T higher than ULN * Cardiac failure NYHA III or above * Coronary artery left main stenosis \>50% * Emergency coronary angiography(CAG) is needed * Serious arrhythmia or tachycardia * Secondary hyperlipidemia * Familial hypercholestrolemia * Uncontrolled severe hypertension (≥200/110 mmHg) * Uncontrolled diabetes (HbA1c ≥9.5%) * Triglyceride ≥500 mg/dL (5.65 mmol/L) * Active hepatic disease or hepatic function impairment, ALT≥3ULN * Serum creatinine \>177 µmol/L (2.0 mg/dL) * Myalgia or blood CK ≥5ULN * WBC \< 4×10e9/L，or PLT \< 100\*10e9/L。 * Participation in the the course of plan and/or procedure of this study * Previous participation in the study treatment * Participation in other clinical studies in the past 3 months * Pregnant or breast-feeding women, women with child-bearing potential who did not use drugs or devices for contraception, or women with positive urine pregnancy test (human chorionic gonadotropin \[HCG\]) * History of malignant tumors (exception: recovered more than 10 years or only basal cell carcinoma or squamous cell carcinoma); females with a history of cervical atypical hyperplasia (exception: 3 consecutive cervical smear tests normal prior to enrolment) * History of alcohol and/or drug abuse in recent 5 years * Any serious or unstable physical or psychological conditions, in the opinion of the investigator, would compromise the safety of the patient or the participation in this study * Use of concomitant medications prohibited in this study ( Erythromycin, clarithromycin, erythromycin ethylsuccinate, sulfaphenazole; Fluconazole, ketoconazole, itraconazole; Niacin / nicotinic acid(including vitamins/food additives containing niacin / nicotinic acid \>50mg), probucol, clofibrate, cholestyramine, colestipol hydrochloride, ezetimibe, fenofibrate, gemfibrozil, atorvastatin(exception: study medication)，lovastatin, pravastatin, rosuvastatin (exception: study medication) , Simvastatin, fluvastatin, fish oil (any dose), lipid-lowering supplements and food additives; Cyclosporine; Protease inhibitors) * Use of periodic hormone replacement treatment(HRT), oral contraceptives(OCTs), long-acting progesterone, or in recent 3 months non-periodic HRT or OCTs * Patients with any condition which, in the investigator's judgment, might increase the risk to the subject for any adverse event or abnormal laboratory finding